Rac-Tovorafenib | CAS 1097250-07-1 - Request Quote
Rac-Tovorafenib
| SZ CAT No: | SZ-T202053 |
| CAS No | 1097250-07-1 |
| Mol.F. | C17H12Cl2F3N7O2S |
| Mol.Wt. |
506.3 |
| Inv. Status |
Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rac-Tovorafenib is chemically 2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide. Rac-Tovorafenib is supplied with detailed characterization data compliant with regulatory guideline. Rac-Tovorafenib can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tovorafenib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 1097250-07-1
Purchase 1097250-07-1
Order 1097250-07-1
Enquire 1097250-07-1
price of 1097250-07-1
1097250-07-1 Supplier
1097250-07-1 Manufacturer
1097250-07-1 Exporter
buy high quality Rac-Tovorafenib
Purchase Rac-Tovorafenib
Rac-Tovorafenib suppliers
Rac-Tovorafenib manufacturers
Rac-Tovorafenib price
Order Rac-Tovorafenib
Enquire Rac-Tovorafenib
Rac-Tovorafenib cost
Rac-Tovorafenib Supplier
Rac-Tovorafenib Distributor
Rac-Tovorafenib for Method Validation
Tovorafenib Reference Standard
Rac-Tovorafenib for ANDA Filing
Rac-Tovorafenib for Forced Degradation Studies
Rac-Tovorafenib Identification Standards
Rac-Tovorafenib for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.